Reyvow 50 mg/1 (Lasmiditan TABLET) 50 mg/1

Reyvow (lasmiditan) 50 mg tablets are used for acute migraine treatment. This oral medication is designed to provide relief from migraine headaches. Learn more about its uses and effects.

Strength

50 mg/1

Pack Size

1 BLISTER PACK in 1 CARTON (0002-4312-61) / 4 TABLET in 1 BLISTER PACK

Manufacturer / TM Owner

Eli Lilly and Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Reyvow is primarily used for the acute treatment of migraines in adults. It is not intended for preventive use. Lasmiditan works by targeting specific pathways involved in migraine attacks. People often ask, 'What is Reyvow used for?' and the answer is focused on providing relief from migraine pain.

Side Effects

Common effects of Reyvow may include dizziness, fatigue, and nausea. Some users report feeling lightheaded or experiencing a sense of relaxation. These effects can vary from person to person and are not experienced by everyone who takes the medication.

Precautions & Warnings

Reyvow should be handled with care. It is important to follow the guidance of a healthcare provider when using this medication. Avoid activities that require mental alertness until you know how Reyvow affects you. Keep the tablets in a safe place, away from children and pets.

Avoid Interactions

Reyvow may interact with other medications, including strong CYP3A4 inhibitors and inducers. It is advisable to discuss all current medications with a healthcare provider before starting Reyvow. Alcohol and certain other substances may also interact with lasmiditan, so caution is recommended.

Frequently Asked Questions

Reyvow is used for the acute treatment of migraines in adults. It is not intended for preventive use.

Reyvow is taken orally, typically as directed by a healthcare provider. Always follow the prescribed dosage and instructions.

Common side effects may include dizziness, fatigue, and nausea. These effects can vary from person to person.

Reyvow may interact with other medications, so it is important to discuss all current medications with a healthcare provider.

Reyvow is intended for acute migraine treatment and not for long-term use. Always consult a healthcare provider for personalized advice.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.